Immunotherapy of angiogenesis with DNA vaccines

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The understanding of the molecular mechanisms of tumor neovascularization has identified several important molecular targets that are specifically expressed on tumor neovasculature but not on physiological neovasculature. These molecular targets can potentially be used in the development of novel therapeutic approaches against tumor angiogenesis. Immunotherapy targeting angiogenesis has emerged as a potentially promising approach compared to the use of angiogenesis inhibitors due to its ability to afford long-term therapeutic protection. This presents remarkable opportunities for the development of innovative cancer therapies.Immunotherapy using DNA vaccines has gained momentum for antiangiogenesis therapy due to their stability, simplicity and excellent safety profile, and may prove to be a potentially useful strategy for targeting angiogenesis. In the current review, we discuss the various strategies and molecular targets employed in the form of DNA vaccines to target: (1) the endothelial cells within the tumor; (2) biological factors important for angiogenesis; and (3) the extracellular matrix and stromal cells associated with the tumor in order to control tumor angiogenesis in preclinical models.

Original languageEnglish (US)
Title of host publicationAngiogenesis: An Integrative Approach From Science to Medicine
PublisherSpringer US
Pages451-460
Number of pages10
ISBN (Print)9780387715179
DOIs
StatePublished - 2008

Fingerprint

DNA Vaccines
Immunotherapy
Neoplasms
Investigational Therapies
Angiogenesis Inhibitors
Biological Factors
Stromal Cells
Extracellular Matrix
Therapeutics
Endothelial Cells
Safety

Keywords

  • angiogenesis
  • DNA vaccines
  • endothelial cells
  • immunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hung, C-F., Monie, A., & Wu, T. C. (2008). Immunotherapy of angiogenesis with DNA vaccines. In Angiogenesis: An Integrative Approach From Science to Medicine (pp. 451-460). Springer US. https://doi.org/10.1007/978-0-387-71518-6_39

Immunotherapy of angiogenesis with DNA vaccines. / Hung, Chien-Fu; Monie, Archana; Wu, Tzyy Choou.

Angiogenesis: An Integrative Approach From Science to Medicine. Springer US, 2008. p. 451-460.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hung, C-F, Monie, A & Wu, TC 2008, Immunotherapy of angiogenesis with DNA vaccines. in Angiogenesis: An Integrative Approach From Science to Medicine. Springer US, pp. 451-460. https://doi.org/10.1007/978-0-387-71518-6_39
Hung C-F, Monie A, Wu TC. Immunotherapy of angiogenesis with DNA vaccines. In Angiogenesis: An Integrative Approach From Science to Medicine. Springer US. 2008. p. 451-460 https://doi.org/10.1007/978-0-387-71518-6_39
Hung, Chien-Fu ; Monie, Archana ; Wu, Tzyy Choou. / Immunotherapy of angiogenesis with DNA vaccines. Angiogenesis: An Integrative Approach From Science to Medicine. Springer US, 2008. pp. 451-460
@inbook{59a9f38f8c6d4c9280f15512ac3ce2b2,
title = "Immunotherapy of angiogenesis with DNA vaccines",
abstract = "The understanding of the molecular mechanisms of tumor neovascularization has identified several important molecular targets that are specifically expressed on tumor neovasculature but not on physiological neovasculature. These molecular targets can potentially be used in the development of novel therapeutic approaches against tumor angiogenesis. Immunotherapy targeting angiogenesis has emerged as a potentially promising approach compared to the use of angiogenesis inhibitors due to its ability to afford long-term therapeutic protection. This presents remarkable opportunities for the development of innovative cancer therapies.Immunotherapy using DNA vaccines has gained momentum for antiangiogenesis therapy due to their stability, simplicity and excellent safety profile, and may prove to be a potentially useful strategy for targeting angiogenesis. In the current review, we discuss the various strategies and molecular targets employed in the form of DNA vaccines to target: (1) the endothelial cells within the tumor; (2) biological factors important for angiogenesis; and (3) the extracellular matrix and stromal cells associated with the tumor in order to control tumor angiogenesis in preclinical models.",
keywords = "angiogenesis, DNA vaccines, endothelial cells, immunotherapy",
author = "Chien-Fu Hung and Archana Monie and Wu, {Tzyy Choou}",
year = "2008",
doi = "10.1007/978-0-387-71518-6_39",
language = "English (US)",
isbn = "9780387715179",
pages = "451--460",
booktitle = "Angiogenesis: An Integrative Approach From Science to Medicine",
publisher = "Springer US",

}

TY - CHAP

T1 - Immunotherapy of angiogenesis with DNA vaccines

AU - Hung, Chien-Fu

AU - Monie, Archana

AU - Wu, Tzyy Choou

PY - 2008

Y1 - 2008

N2 - The understanding of the molecular mechanisms of tumor neovascularization has identified several important molecular targets that are specifically expressed on tumor neovasculature but not on physiological neovasculature. These molecular targets can potentially be used in the development of novel therapeutic approaches against tumor angiogenesis. Immunotherapy targeting angiogenesis has emerged as a potentially promising approach compared to the use of angiogenesis inhibitors due to its ability to afford long-term therapeutic protection. This presents remarkable opportunities for the development of innovative cancer therapies.Immunotherapy using DNA vaccines has gained momentum for antiangiogenesis therapy due to their stability, simplicity and excellent safety profile, and may prove to be a potentially useful strategy for targeting angiogenesis. In the current review, we discuss the various strategies and molecular targets employed in the form of DNA vaccines to target: (1) the endothelial cells within the tumor; (2) biological factors important for angiogenesis; and (3) the extracellular matrix and stromal cells associated with the tumor in order to control tumor angiogenesis in preclinical models.

AB - The understanding of the molecular mechanisms of tumor neovascularization has identified several important molecular targets that are specifically expressed on tumor neovasculature but not on physiological neovasculature. These molecular targets can potentially be used in the development of novel therapeutic approaches against tumor angiogenesis. Immunotherapy targeting angiogenesis has emerged as a potentially promising approach compared to the use of angiogenesis inhibitors due to its ability to afford long-term therapeutic protection. This presents remarkable opportunities for the development of innovative cancer therapies.Immunotherapy using DNA vaccines has gained momentum for antiangiogenesis therapy due to their stability, simplicity and excellent safety profile, and may prove to be a potentially useful strategy for targeting angiogenesis. In the current review, we discuss the various strategies and molecular targets employed in the form of DNA vaccines to target: (1) the endothelial cells within the tumor; (2) biological factors important for angiogenesis; and (3) the extracellular matrix and stromal cells associated with the tumor in order to control tumor angiogenesis in preclinical models.

KW - angiogenesis

KW - DNA vaccines

KW - endothelial cells

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84885793339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885793339&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-71518-6_39

DO - 10.1007/978-0-387-71518-6_39

M3 - Chapter

AN - SCOPUS:84885793339

SN - 9780387715179

SP - 451

EP - 460

BT - Angiogenesis: An Integrative Approach From Science to Medicine

PB - Springer US

ER -